PDL BioPharma Inc
932 Southwood Blvd.
Incline Village
NV
89451
United States
39 articles about PDL BioPharma Inc
-
PDL BioPharma to Announce 2019 Fourth Quarter and Full Year Financial Results on March 11, 2020
3/4/2020
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its 2019 fourth quarter and full year financial results for the period ended December 31, 2019 , on Wednesday, March 11, 2020 , after market close.
-
PDL BioPharma Enters into Cooperation Agreement with Engine Capital
2/28/2020
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced it has entered into a cooperation agreement with Engine Capital Management LP (together with its affiliates, "Engine"), which owns approximately 5.5% of the Company's outstanding shares, pursuant to which Alan L. Bazaar will immediately join PDL's Board of Directors as a Class III director serving until the Company's 2022 Annual Meeting of Stockholders.
-
PDL BioPharma to Participate in the Cowen and Company 40th Annual Health Care Conference
2/25/2020
INCLINE VILLAGE, Nev. , Feb. 25, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, will present at the Cowen and Company 40 th Annual Health Care Conference on Tuesday, March 3, 2020 at 10:40 a.m. Eastern time ( 7:40 a.m. Pacific time ). The conference is being h
-
PDL BioPharma Announces Upcoming Changes to its Board of Directors
12/19/2019
PDL BioPharma, Inc. announced upcoming changes to the Company's Board of Directors.
-
PDL BioPharma Board of Directors Increases Share and Note Repurchase Authorization to $275 Million
12/16/2019
The cash and common stock to be distributed by PDL in this exchange will utilize approximately $143.8 million of the original $200 million authorization based on the closing price of PDL's common stock on December 12, 2019.
-
PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024
12/13/2019
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of its outstanding 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes") for (i) cash in an aggregate amount of $98.0 million
-
PDL BioPharma Announces Completion of Strategic Review Process
12/9/2019
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced today that it has completed the strategic review process that it initiated in September.
-
PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®
12/3/2019
The first milestone was the resubmission of the Amphora New Drug Application to the U.S. Food and Drug Administration for the prevention of pregnancy that was announced November 26, 2019.
-
PDL BioPharma Reaffirms Commitment To Shareholder Value Creation
11/14/2019
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today issued the following statement in response to Engine Capital LP's ("Engine") escalation of its public campaign criticizing PDL's strategic direction:
-
PDL BioPharma Reports 2019 Third Quarter Financial Results
11/6/2019
Revenues of $44.2 million includes continued growth from LENSAR and strong contribution from royalty assets
-
PDL BioPharma to Announce Third Quarter 2019 Financial Results on November 6, 2019
10/30/2019
A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.
-
PDL BioPharma Responds to Letter from Engine Capital
10/24/2019
Harold E. Selick, Ph.D., Chairman of the Board of Directors of PDL BioPharma, has sent the following letter to Engine Capital, LP.
-
PDL BioPharma to Participate in the 2019 Cantor Fitzgerald Global Healthcare Conference
9/26/2019
The conference is being held at the Intercontinental New York Barclay Hotel.
-
PDL BioPharma Announces Private Exchange of Approximately $86.1 Million of Convertible Notes Due 2024
9/13/2019
PDL BioPharma, Inc. announced that it has entered into separate privately negotiated transactions to exchange approximately $86.1 million in aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 for approximately $86.1 million in aggregate original principal amount of new 2.75% Convertible Senior Notes due 2024 together with an aggregate of approximately $6.0 million of cash.
-
PDL BioPharma Announces Favorable Decision in Wellstat Diagnostics Litigation
9/11/2019
Today's decision resolved a dispute regarding the validity and enforceability of guarantees on the loan made by related entities of Wellstat Diagnostics
-
PDL BioPharma Reports 2019 Second Quarter Financial Results
8/7/2019
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2019
-
PDL BioPharma to Announce Second Quarter 2019 Financial Results on August 7, 2019
7/31/2019
A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.
-
PDL BioPharma Announces Departure of CFO
6/25/2019
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced the resignation of Chief Financial Officer, Peter Garcia, who will be leaving the Company effective August 15, 2019.
-
Natasha A. Hernday Elected to PDL BioPharma's Board of Directors
6/24/2019
This appointment increases PDL's Board membership to nine, including seven independent Directors.